Research
Hormonal
Visceral adipose tissue volume, rather than total body fat or subcutaneous fat, is the primary driver of insulin resistance and the metabolic syndrome through the flux of free fatty acids and TNF-alpha to the liver and peripheral tissues.
Focus on reducing visceral fat through lifestyle changes (diet and exercise) rather than just chasing a specific BMI number. Visceral fat is the key driver of insulin resistance, and reducing it improves metabolic health even if total body weight doesn't change drastically.
GoodSupportsHIGH confidence
We were able to show that insulin sensitivity, as measured by the euglycemic hyperinsulinemic clamp, was negatively correlated with visceral adipose tissue volume in both men and women... and had no significant correlation with subcutaneous adipose tissue volume... The mechanism by which an increase in visceral adipose mass causes insulin resistance... is postulated that insulin resistance results from the direct drainage of free fatty acids and perhaps tumor necrosis factor alpha (TNFa) from the visceral adipose tissue through the portal vein into the liver and beyond into the peripheral tissues.
Why this rating
Strong observational and mechanistic data from multiple studies cited (CT scans, clamps), though causality in humans is complex.
Source
Insulin Resistance and Its Treatment by Thiazolidinediones
Harold E. Lebovitz · Recent Progress in Hormone Research · 2001
DOI 10.1210/rp.56.1.265
narrative_reviewCited 183×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →